**1-(4-carboxyethylphenyl)-3,3-dimethyltriazene** is a synthetic compound, also known as **dicarbazine**, that is a **prodrug** of the **anticancer agent, 1-(4-carboxyphenyl)-3,3-dimethyltriazene (Altretamine).**
**Importance in Research:**
* **Prodrug for Altretamine:** Dicarbazine is a prodrug, which means it is inactive in its original form but is converted into an active drug (Altretamine) within the body. The prodrug design helps to improve Altretamine's pharmacokinetic properties, such as absorption, distribution, and metabolism.
* **Cancer Treatment:** Altretamine is an alkylating agent that has been used to treat various cancers, including ovarian cancer, breast cancer, and melanoma.
* **Mechanism of Action:** Altretamine works by alkylating DNA, which damages the cancer cells and prevents their proliferation.
* **Clinical Trials:** Dicarbazine has been investigated in clinical trials as a potential treatment for various cancers. Studies have evaluated its effectiveness and safety in treating different tumor types.
* **Pharmacokinetic Studies:** Research on dicarbazine has focused on understanding its pharmacokinetics, including its absorption, distribution, metabolism, and excretion. This knowledge is essential for optimizing its clinical use.
* **Drug Delivery:** Dicarbazine's prodrug nature allows for targeted drug delivery, which could improve the effectiveness of Altretamine and minimize side effects.
**Other Research Applications:**
* **Synthesis and Development of New Anticancer Agents:** Research on dicarbazine has provided valuable insights into the synthesis and development of new anticancer agents with improved pharmacological properties.
* **Drug Discovery:** Dicarbazine serves as a lead compound for the identification and development of novel anticancer drugs.
In summary, 1-(4-carboxyethylphenyl)-3,3-dimethyltriazene (dicarbazine) is a significant research compound due to its role as a prodrug for the anticancer agent Altretamine. It has potential for improving the treatment of various cancers and has contributed to research on drug development and targeted drug delivery.
| ID Source | ID |
|---|---|
| PubMed CID | 30700 |
| CHEMBL ID | 1331788 |
| MeSH ID | M0047522 |
| Synonym |
|---|
| 1(4-carbethoxyphenyl)-3,3-dimethyltriazene |
| 1-(p-carboxyaetylphenyl)-3,3-dimethyltriazen [german] |
| benzoic acid, p-(3,3-dimethyl-1-triazeno)-, ethyl ester |
| benzoic acid, 4-(3,3-dimethyl-1-triazenyl)-, ethyl ester |
| triazene, 1-(p-ethylcarboxyphenyl)-3,3-dimethyl- |
| nsc 86445 |
| at 2052 |
| benzoic acid, p-(3-dimethyltriazeno)-, ethyl ester |
| ethyl 4-(3,3-dimethyl-1-triazenyl)benzoate |
| 1-(p-carbethoxyphenyl)-3,3-dimethyltriazine |
| benzoic acid,3-dimethyl-1-triazenyl)-, ethyl ester |
| benzoic acid,3-dimethyl-1-triazeno)-, ethyl ester |
| nsc-86445 |
| 1-(4-carbethoxyphenyl)-3,3-dimethyltriazene |
| nsc86445 |
| 21600-51-1 |
| 3,3-dimethyl-1-(4-carbethoxyphenyl)triazene |
| smr000429466 |
| MLS000767141 , |
| STK038377 |
| ethyl 4-[(1e)-3,3-dimethyltriaz-1-en-1-yl]benzoate |
| ethyl 4-(dimethylaminodiazenyl)benzoate |
| NCGC00246361-01 |
| AKOS005382918 |
| 1-(p-carboxyaetylphenyl)-3,3-dimethyltriazen |
| 1-(p-carboxyethylphenyl)-3,3-dimethyltriazine |
| HMS2806O24 |
| CHEMBL1331788 |
| DTXSID40876488 |
| ethylbenzoate433dimethyltriazenyl |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 19.0115 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| BRCA1 | Homo sapiens (human) | Potency | 12.5893 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 23.0999 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 10.0000 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 4.4668 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 5.6234 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 9.2000 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 2.8184 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
| geminin | Homo sapiens (human) | Potency | 0.1636 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 0.5623 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||